New embryo base-editing studies raise safety hopes and ethical questions

In the summer of 2026, two independent labs demonstrated the use of base-editing—a more precise form of CRISPR—on human embryos. Kathy Niakan’s Cambridge team focused on the NANOG gene essential for early body formation, while Dieter Egli’s Columbia group edited genes associated with high cholesterol and haemoglobin production. Both reported reduced off-target chromosome errors compared with conventional CRISPR, though low-level mosaicism persisted.

Scientists such as Robin Lovell-Badge acknowledge the progress but stress the need for further improvement. Bioethicists like Pascal Borry question where therapy ends and enhancement begins, raising issues of consent and potential stigma. Others argue that existing techniques like pre-implantation genetic diagnosis may render embryo editing unnecessary, though some see research value for understanding infertility. The studies reignite calls for careful regulation rather than outright bans.